{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:27:14Z","timestamp":1787869634504,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejps.2026.107477","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:05:34Z","timestamp":1771358734000},"page":"107477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Optimization and aerodynamic performance of nebulizable pirfenidone-loaded human serum albumin nanoparticles for targeted pulmonary delivery"],"prefix":"10.1016","volume":"220","author":[{"given":"Jia-Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hsuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Chun","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Kuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Ian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiou-Lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-5289","authenticated-orcid":false,"given":"Yi-Ping","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107477_bib0001","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1513\/AnnalsATS.202102-123ED","article-title":"Broad adoption of antifibrotics in idiopathic pulmonary fibrosis: still a long way to go","volume":"18","author":"Assayag","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"6","key":"10.1016\/j.ejps.2026.107477_bib0002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/mi.2012.74","article-title":"The alveolar macrophages in asthma: a double-edged sword","volume":"5","author":"Balhara","year":"2012","journal-title":"Mucosal. Immunol."},{"key":"10.1016\/j.ejps.2026.107477_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106509","article-title":"Preparation and evaluation of sustained release pirfenidone-loaded microsphere dry powder inhalation for treatment of idiopathic pulmonary fibrosis","volume":"188","author":"Bao","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107477_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12931-020-01585-9","article-title":"Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned","volume":"22","author":"Bianco","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejps.2026.107477_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition\u2013what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107477_bib0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2014.11.008","article-title":"Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer","volume":"197","author":"Choi","year":"2015","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2026.107477_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113952","article-title":"In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols","volume":"177","author":"Chow","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107477_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-3659(02)00370-X","article-title":"Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features","volume":"86","author":"Dailey","year":"2003","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.ejps.2026.107477_bib0009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2026.107477_bib46","series-title":"The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction","author":"Finlay","year":"2001"},{"key":"10.1016\/j.ejps.2026.107477_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7861\/clinmedicine.16-1-42","article-title":"Therapeutic advances in idiopathic pulmonary fibrosis","volume":"16","author":"Fraser","year":"2016","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejps.2026.107477_bib0011","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijbiomac.2016.01.082","article-title":"Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity","volume":"86","author":"Ghosh","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2026.107477_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2019.09.002","article-title":"Challenges and strategies in drug delivery systems for treatment of pulmonary infections","volume":"144","author":"Ho","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107477_bib0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107477_bib0014","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.2174\/1381612821666150923095742","article-title":"Nano-therapeutics for the lung: state-of-the-art and future perspectives","volume":"21","author":"Iyer","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2026.107477_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124837","article-title":"Design and development of DSPE-PEG2000\/DPPC disk-like micelles for targeted delivery of icariin phytochemical in pulmonary fibrosis","volume":"667","author":"Jiang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107477_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11095-019-2732-2","article-title":"Aerosol pirfenidone pharmacokinetics after inhaled delivery in aheep: a viable approach to treating idiopathic pulmonary fibrosis","volume":"37","author":"Kaminskas","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107477_bib0017","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","article-title":"Albumin nanostructures as advanced drug delivery systems","volume":"13","author":"Karimi","year":"2016","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107477_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12951-020-00731-1","article-title":"Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention","volume":"19","author":"Kaur","year":"2021","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejps.2026.107477_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114005","article-title":"Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis","volume":"385","author":"Kim","year":"2025","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2026.107477_bib0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1248\/cpb.c17-00838","article-title":"Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives","volume":"66","author":"Kimura","year":"2018","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejps.2026.107477_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2026.107477_bib0022","article-title":"Exploring the albumin nanoparticles as the next-generation advanced multifunctional biomaterials for inhalation lung therapy: facts, prospects, and challenges","author":"Kumbhar","year":"2025","journal-title":"Biomed. Mater. Devices"},{"key":"10.1016\/j.ejps.2026.107477_bib47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107477_bib0023","article-title":"Inhaled pH-responsive polymyxin B-loaded albumin nanoparticles against pneumonia caused by carbapenem resistant Klebsiella pneumoniae","volume":"31","author":"Li","year":"2025","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.ejps.2026.107477_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125074","article-title":"Pirfenidone microcrystals for pulmonary delivery: regulation of the precipitation behavior in the supercooled droplet","volume":"669","author":"Lu","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2026.107477_bib0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1248\/cpb.c21-01024","article-title":"The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors","volume":"70","author":"Ishima","year":"2022","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejps.2026.107477_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00262-2023","article-title":"Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial","volume":"62","author":"Molina-Molina","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2026.107477_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.593620","article-title":"Low-dose of intrapulmonary pirfenidone improves human transforming growth factorbeta1-driven lung fibrosis","volume":"11","author":"Okano","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107477_bib0029","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s11095-013-0997-4","article-title":"Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis","volume":"30","author":"Onoue","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107477_bib0030","article-title":"Albumin-based formononetin nanomedicines for lung injury and fibrosis therapy via blocking macrophage pyroptosis","volume":"20","author":"Ouyang","year":"2023","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.ejps.2026.107477_bib0031","first-page":"225","article-title":"RP-HPLC and UV spectrophotometric methods for estimation of pirfenidone in pharmaceutical formulations","volume":"76","author":"Parmar","year":"2014","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107477_bib0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/pharmaceutics16020161","article-title":"Nano-formulations for pulmonary delivery: past, present, and future perspectives","volume":"16","author":"Peng","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107477_bib0033","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2013.0931","article-title":"Interaction of colloidal nanoparticles with their local environment: the (ionic) nanoenvironment around nanoparticles is different from bulk and determines the physico-chemical properties of the nanoparticles","volume":"11","author":"Pfeiffer","year":"2014","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.ejps.2026.107477_bib0034","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.2147\/IJN.S467876","article-title":"Albumin nanoparticle-based drug delivery systems","volume":"19","author":"Qu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2026.107477_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12938-019-0624-7","article-title":"Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation","volume":"18","author":"Qu","year":"2019","journal-title":"Biomed. Eng. Online"},{"key":"10.1016\/j.ejps.2026.107477_bib0036","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejps.2026.107477_bib0037","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejps.2026.107477_bib0038","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-016-1887-3","article-title":"Development of an improved inhalable powder formulation of pirfenidone by spray-drying: In vitro characterization and pharmacokinetic profiling","volume":"33","author":"Seto","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107477_bib0039","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/02652048.2011.635218","article-title":"Albumin nanoparticles with predictable size by desolvation procedure","volume":"29","author":"von Storp","year":"2012","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2026.107477_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12951-023-01971-7","article-title":"Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects","volume":"21","author":"Wan","year":"2023","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejps.2026.107477_bib0041","article-title":"Pulmonary inhalation for disease treatment: basic research and clinical translations","volume":"25","author":"Wang","year":"2024","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.ejps.2026.107477_bib0042","first-page":"e744","article-title":"Pulmonary fibrosis: pathogenesis and therapeutic strategies","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm. 2020"},{"key":"10.1016\/j.ejps.2026.107477_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124096","article-title":"Inhalable FN-binding liposomes or liposome-exosome hybrid bionic vesicles encapsulated microparticles for enhanced pulmonary fibrosis therapy","volume":"656","author":"Wang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107477_bib0044","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-5173(99)00370-1","article-title":"Desolvation process and surface characterisation of protein nanoparticles","volume":"194","author":"Weber","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107477_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.05.269","article-title":"In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery","volume":"210","author":"Woods","year":"2015","journal-title":"J. Control Release"}],"updated-by":[{"DOI":"10.1016\/j.ejps.2026.107522","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000}},{"DOI":"10.1016\/j.ejps.2026.107522","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:30:35Z","timestamp":1777591835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":46,"alternative-id":["S0928098726000515"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107477","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization and aerodynamic performance of nebulizable pirfenidone-loaded human serum albumin nanoparticles for targeted pulmonary delivery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107477"}}